Disc Medicine, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended December 31, 2025:
| Name and Title | Type of Trading Arrangement | Action Taken(Date of Action) | Duration or End Date | Aggregate Number of Securities to be Sold | Description of Trading Arrangement |
|---|---|---|---|---|---|
| William Savage, M.D., Ph.D.Chief Medical Officer | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Adoption(October 2, 2025) | End Date(May 1, 2026) | Up to 16,3651 | Sale |
(1) The aggregate number of shares available for sale cannot yet be determined, as it will be reduced by the number of shares sold to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs). For disclosure purposes, the figures in this table reflect the maximum number of shares underlying the RSUs, without deducting shares that may be sold to cover taxes.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.